The rationale behind this decision was to investigate the relationship between GM-CBF and the neuropathological mechanisms in AD while the underlying pathology in Aβ-negative MCI patients is independent of amyloid and tau accumulation. This evidence concerns the gene MAPT and Alzheimer disease.